Genome editing company Precision proposes $100M IPO

With plans to bring an allogeneic CAR T immunotherapy into the clinic, Precision BioSciences Inc. (Durham, N.C.) proposed March 1 to raise up to $100 million in an IPO

Read the full 292 word article

User Sign In